Literature DB >> 11173064

Evaluation of native GABA(A) receptors containing an alpha 5 subunit.

M Li1, A Szabo, H C Rosenberg.   

Abstract

The type A receptor for gamma-aminobutyric acid (GABA), or GABA(A) receptor, is a pentamer of highly variable quaternary structure. It includes two alpha subunits, drawn from a pool of six genes, which largely determine benzodiazepine pharmacology of the receptor. In brain sections, both [(3)H]RY-80 (ethyl-8-acetylene-5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5a][1,4]benzodiazepine-3-carboxylate) and [(3)H]L-655,708 (ethyl (S)-11,12,13,13a-tetrahydro-7-methoxy-9-oxo-9H-imidazo[1,5-a]pyrrolo[2,1-c][1,4]benzodiazepine-1-carboxylate), which are selective for the benzodiazepine site of alpha 5 subunit-containing receptors, showed high-affinity, specific binding, but to fewer regions than did the nonselective benzodiazepine, [(3)H]flunitrazepam. The pattern mirrored alpha 5 mRNA distribution, and was similar to that previously reported for [(3)H]L-655,708 binding. Displacement of [(3)H]RY-80 bound to hippocampal homogenates, and of [(3)H]flunitrazepam bound to cerebellar and hippocampal homogenates showed comparable displacement by flumazenil (K(i)'s 5--7 nM). However, the K(i)'s for diazepam and for clobazam to displace [(3)H]RY-80 binding in hippocampus were about fourfold higher than for [(3)H]flunitrazepam, and the K(i) for clonazepam was sixfold larger, suggesting that these benzodiazepine receptor agonists bind with relatively lower affinity at hippocampal alpha 5-containing receptors.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11173064     DOI: 10.1016/s0014-2999(01)00751-8

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  6 in total

1.  Allosteric modulation of related ligand-gated ion channels synergistically induces long-term potentiation in the hippocampus and enhances cognition.

Authors:  Timothy B Johnstone; Zhenglin Gu; Ryan F Yoshimura; Anne-Sophie Villegier; Derk J Hogenkamp; Edward R Whittemore; Jin-Cheng Huang; Minhtam B Tran; James D Belluzzi; Jerrel L Yakel; Kelvin W Gee
Journal:  J Pharmacol Exp Ther       Date:  2010-12-15       Impact factor: 4.030

2.  α5GABAA subunit-containing receptors and sweetened alcohol cue-induced reinstatement and active sweetened alcohol self-administration in male rats.

Authors:  Cassie M Chandler; Jaren Reeves-Darby; Sherman A Jones; J Abigail McDonald; Guanguan Li; Md T Rahman; James M Cook; Donna M Platt
Journal:  Psychopharmacology (Berl)       Date:  2019-01-12       Impact factor: 4.530

3.  Pharmacological plasticity of GABA(A) receptors at dentate gyrus synapses in a rat model of temporal lobe epilepsy.

Authors:  Claire Leroy; Pierrick Poisbeau; A Florence Keller; Astrid Nehlig
Journal:  J Physiol       Date:  2004-03-19       Impact factor: 5.182

4.  Clobazam as an adjunctive therapy in treating seizures associated with Lennox-Gastaut syndrome.

Authors:  Jennifer T Leahy; Catherine J Chu-Shore; Janet L Fisher
Journal:  Neuropsychiatr Dis Treat       Date:  2011-11-11       Impact factor: 2.570

5.  Basmisanil, a highly selective GABAA-α5 negative allosteric modulator: preclinical pharmacology and demonstration of functional target engagement in man.

Authors:  Joerg F Hipp; Frederic Knoflach; Robert Comley; Theresa M Ballard; Michael Honer; Gerhard Trube; Rodolfo Gasser; Eric Prinssen; Tanya L Wallace; Andreas Rothfuss; Henner Knust; Sian Lennon-Chrimes; Michael Derks; Darren Bentley; Lisa Squassante; Stephane Nave; Jana Nöldeke; Christoph Wandel; Andrew W Thomas; Maria-Clemencia Hernandez
Journal:  Sci Rep       Date:  2021-04-08       Impact factor: 4.379

6.  The Case for Clinical Trials with Novel GABAergic Drugs in Diabetes Mellitus and Obesity.

Authors:  Ferenc A Antoni
Journal:  Life (Basel)       Date:  2022-02-21
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.